KOVE Raises €1.7M for Foetal Surgery

Some of the most important healthtech opportunities sit inside narrow, high-risk clinical workflows.

What happened

Zurich-based KOVE Medical secured €1.7M, equivalent to about CHF 1.6M, to develop an implantable medical device designed to reduce preterm-birth risk after foetal surgery.

The funding supports development toward first-in-human studies. The company is focused on a specialised medtech problem rather than a broad consumer-health application.

Why it matters

This is a small but useful healthtech item. Foetal surgery is complex, and complications can create serious risks for both pregnancy and newborn outcomes.

A device that reduces preterm-birth risk after these procedures would address a highly specific but meaningful clinical need.

The bigger picture

Healthtech funding is often dominated by AI platforms and digital care models, but device innovation remains important. Focused medtech startups can still attract capital when they target well-defined procedures, measurable outcomes and clear clinical pathways.